Compare interventions

Use the same six evidence dimensions for both. This prevents a strong animal result for one product being compared with a human clinical result for another.

First intervention

versus

Second intervention

Amino acids and redox biology

GlyNAC

Early human evidence

Small human studies are intriguing, but the claims currently outrun the sample sizes.

Human clinical outcomes Limited

Human biomarkers Moderate

Animal lifespan Preliminary

Mechanistic plausibility Moderate

Safety certainty Limited

Direct longevity relevance Preliminary

Verdict: GlyNAC combines glycine with N-acetylcysteine, two substrates involved in glutathione synthesis. Small studies in older adults have reported changes in glutathione status, oxidative stress, mitochondrial measures and some functional outcomes. These findings justify larger independent trials, not declarations that multiple hallmarks of ageing have been reversed.

Open full dossier

NAD+ precursor

NMN

Early human evidence

Raises NAD-related biomarkers; broad healthspan benefits have not followed reliably.

Human clinical outcomes Preliminary

Human biomarkers Moderate

Animal lifespan Limited

Mechanistic plausibility Moderate

Safety certainty Limited

Direct longevity relevance Preliminary

Verdict: Nicotinamide mononucleotide can raise NAD-related measures in humans, which confirms biological activity. Trials have reported selected metabolic or functional effects, but results are mixed, studies are generally short, and no human evidence shows slower ageing or longer life.

Open full dossier